Biomarkers for early detection of PDAC
Research type
Research Study
Full title
Early detection of pancreatic adenocarcinoma (PDAC) using a panel of biomarkers
IRAS ID
220877
Contact name
Tatjana Crnogorac-Jurcevic
Contact email
Sponsor organisation
Queen Mary University of London
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
The majority of patients with pancreatic cancer die within a few months of diagnosis and less than 1% are cured; mainly because pancreatic cancer is usually diagnosed late. Patients diagnosed early have much better chance of cure. Current diagnostic methods can be time consuming and involve uncomfortable procedures, which has led to an increasing interest in better screening tests. Urine is easily obtainable body fluid; in our study we want to investigate the usefulness of new urinary biomarkers in early detection of this disease.
We have recently described a three-biomarker panel (REG1, TFF1, LYVE1) for early detection of pancreatic cancer through proteomic profiling of clinical urine specimens and validated it in a large collection of pancreatic cancer and control patients. To improve even further the specificity and sensitivity of this test, we plan to compare these results with the performance of other biomarkers that we have recently identified, such as microRNAs and volatile organic compounds. We would like to combine the most promising biomarker classes in order to achieve highly accurate testing for early pancreatic cancer detection.REC name
North East - York Research Ethics Committee
REC reference
18/NE/0070
Date of REC Opinion
8 Feb 2018
REC opinion
Favourable Opinion